Filtros de búsqueda

Lista de obras de

"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.

artículo científico publicado en 2018

10 years of progress in chronic myelogenous leukemia.

artículo científico publicado en 2012

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

artículo científico publicado en 2005

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

artículo científico publicado en 2017

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase

artículo científico

A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia

artículo científico publicado en 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2010

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat

artículo científico publicado en 2015

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes

artículo científico publicado en 2014

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

artículo científico publicado en 2014

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2016

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

artículo científico publicado en 2017

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2011

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

scientific article published on 23 July 2013

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

artículo científico publicado en 2016

Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates

artículo científico publicado en 2013

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

artículo científico publicado en 2013

Adherence to BCR-ABL inhibitors: issues for CML therapy

artículo científico publicado en 2012

Advances in the biology and therapy of patients with chronic myeloid leukaemia

scientific article published on September 2009

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

artículo científico publicado en 2015

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

artículo científico publicado en 2013

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis

artículo científico publicado en 2014

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2014

Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors

artículo científico publicado en 2011

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

artículo científico publicado en 2006

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

artículo científico publicado en 2016

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

artículo científico publicado en 2012

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

artículo científico publicado en 2010

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

artículo científico publicado en 2013

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD

artículo científico publicado en 2014

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

artículo científico publicado en 2017

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies

artículo científico publicado en 2010

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

artículo científico publicado en 2018

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

artículo científico publicado en 2008

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

artículo científico publicado en 2012

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

artículo científico publicado en 2008

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

artículo científico publicado en 2012

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

artículo científico publicado en 2007

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

artículo científico publicado en 2016

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

artículo científico publicado en 2010

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

artículo científico publicado en 2012

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

artículo científico publicado en 2014

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

artículo científico publicado en 2016

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

artículo científico publicado en 2018

Chronic myeloid leukemia: First-line drug of choice

artículo científico publicado en 2016

Chronic myeloid leukemia: mechanisms of resistance and treatment

artículo científico publicado en 2011

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

artículo científico publicado en 2017

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

artículo científico

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

artículo científico publicado en 2015

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

artículo científico publicado en 2004

Clinical activity of tipifarnib in hematologic malignancies

artículo científico publicado en 2007

Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective

artículo científico publicado en 2010

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

artículo científico publicado en 2017

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

artículo científico publicado en 2016

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

artículo científico publicado en 2005

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2016

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

artículo científico publicado en 2015

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

artículo científico publicado en 2012

Clofarabine in leukemia

artículo científico publicado en 2010

Clofarabine in the treatment of myelodysplastic syndromes

artículo científico publicado en 2014

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

scientific article published on 26 January 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

artículo científico publicado en 2017

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

artículo científico publicado en 2017

Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients

artículo científico publicado en 2017

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

artículo científico publicado en 2011

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

artículo científico publicado en 2015

Current and emerging treatment options in chronic myeloid leukemia

artículo científico publicado en 2007

Current and future management options for myelodysplastic syndromes

artículo científico publicado en 2010

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

artículo científico publicado en 2010

Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults

artículo científico publicado en 2017

Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment

artículo científico publicado en 2007

Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.

artículo científico publicado en 2014

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

artículo científico publicado en 2007

Dasatinib for the treatment of chronic myeloid leukemia

artículo científico publicado en 2011

Deacetylase inhibitors for the treatment of myelodysplastic syndromes

artículo científico publicado en 2015

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration ⬇️

artículo científico publicado el 24 de agosto de 2010

Development and targeted use of nilotinib in chronic myeloid leukemia.

artículo científico publicado en 2009

Development of a symptom assessment in patients with myelofibrosis: qualitative study findings

article

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

artículo científico publicado en 2016

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up

artículo científico publicado en 2015

Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia

artículo científico publicado en 2015

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

artículo científico publicado en 2007

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

artículo científico publicado en 2012

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

artículo científico publicado en 2016

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

artículo científico publicado en 2013

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

artículo científico publicado en 2013

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

artículo científico publicado en 2013

Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies

artículo científico

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.

artículo científico publicado en 2018

Emerging therapy for the treatment of acute lymphoblastic leukemia

artículo científico publicado en 2010

Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine

artículo científico publicado en 2012

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2015

Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies

artículo científico publicado en 2008

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy

artículo científico publicado en 2013

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2012

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Failure of hypomethylating agent-based therapy in myelodysplastic syndromes

artículo científico publicado en 2011

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

artículo científico publicado en 2009

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency

artículo científico publicado en 2010

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

artículo científico publicado en 2012

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

artículo científico publicado en 2017

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

artículo científico publicado en 2011

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

artículo científico publicado en 2016

Frontline treatment of acute myeloid leukemia in adults

artículo científico publicado en 2016

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

artículo científico publicado en 2014

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

artículo científico publicado en 2017

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

artículo científico publicado en 2013

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

artículo científico publicado en 2008

Imatinib: high dose versus standard dose.

artículo científico publicado en 2009

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

artículo científico publicado en 2016

Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia

artículo científico publicado en 2015

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

artículo científico publicado en 2014

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2016

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2018

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

artículo científico publicado en 2011

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

artículo científico publicado en 2011

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

artículo científico publicado en 2015

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas

artículo científico

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.

artículo científico publicado en 2016

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

artículo científico publicado en 2012

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

artículo científico publicado en 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

artículo científico publicado en 2010

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

artículo científico publicado en 2016

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

artículo científico publicado en 2017

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

artículo científico publicado en 2015

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

artículo científico publicado en 2008

L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.

artículo científico publicado en 2018

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

artículo científico publicado en 2014

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

artículo científico publicado en 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

artículo científico publicado en 2018

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis

artículo científico publicado en 2008

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

artículo científico publicado en 2015

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

artículo científico publicado en 2009

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

artículo científico publicado en 2010

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

artículo científico publicado en 2012

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

artículo científico publicado en 2009

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

artículo científico publicado en 2011

Management of imatinib-resistant patients with chronic myeloid leukemia

artículo científico publicado en 2013

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

artículo científico publicado en 2007

Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy

artículo científico publicado en 2009

Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.

artículo científico publicado en 2017

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

artículo científico publicado en 2011

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

artículo científico publicado en 2013

Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications

artículo científico publicado en 2008

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis

artículo científico publicado en 2012

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

artículo científico publicado en 2017

Mutant BCR-ABL clones in chronic myeloid leukemia

artículo científico publicado en 2011

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

artículo científico publicado en 2014

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

artículo científico publicado en 2007

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

artículo científico publicado en 2017

New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

scientific article published on February 2011

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

artículo científico

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

artículo científico publicado en 2007

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

artículo científico publicado en 2009

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia ⬇️

artículo científico publicado el 13 de noviembre de 2010

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review ⬇️

artículo científico publicado el 15 de junio de 2010

Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

artículo científico publicado en 2009

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

artículo científico publicado en 2018

Novel therapies for relapsed acute lymphoblastic leukemia

artículo científico publicado en 2009

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

artículo científico publicado en 2006

Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?

artículo científico publicado en 2007

Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules

artículo científico publicado en 2008

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

artículo científico publicado en 2012

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

artículo científico publicado en 2013

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

artículo científico publicado en 2016

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

artículo científico publicado en 2011

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

artículo científico publicado en 2010

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

artículo científico publicado en 2017

Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure

artículo científico publicado en 2011

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

artículo científico publicado en 2017

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

artículo científico publicado en 2014

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.

artículo científico publicado en 2010

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

artículo científico publicado en 2016

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

artículo científico publicado en 2016

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

artículo científico publicado en 2016

Pharmacokinetic evaluation of decitabine for the treatment of leukemia

artículo científico publicado en 2011

Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia

artículo científico publicado en 2015

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

artículo científico publicado en 2006

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

artículo científico publicado en 2011

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

artículo científico publicado en 2016

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

artículo científico publicado en 2017

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

scholarly article by Farhad Ravandi et al published November 2018 in Haematologica

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

artículo científico publicado en 2016

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

artículo científico publicado en 2011

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2015

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

artículo científico publicado en 2012

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

artículo científico publicado en 2015

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2014

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

artículo científico publicado en 2014

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

artículo científico publicado en 2011

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

artículo científico publicado en 2017

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

artículo científico publicado en 2014

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

artículo científico publicado en 2015

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

artículo científico publicado en 2012

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.

artículo científico publicado en 2018

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

artículo científico publicado en 2015

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

artículo científico publicado en 2016

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

artículo científico publicado en 2010

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

artículo científico publicado en 2014

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

artículo científico publicado en 2012

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

artículo científico publicado en 2011

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2010

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

artículo científico publicado en 2009

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

artículo científico publicado en 2007

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2012

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

artículo científico publicado en 2015

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

artículo científico publicado en 2011

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

artículo científico publicado en 2016

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

artículo científico publicado en 2017

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

artículo científico publicado en 2015

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes

artículo científico publicado en 2013

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

artículo científico publicado en 2010

Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

artículo científico publicado en 2008

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

artículo científico publicado en 2017

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

artículo científico publicado en 2015

Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia

artículo científico publicado en 2017

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia

artículo científico publicado en 2008

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

artículo científico publicado en 2010

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2009

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

artículo científico publicado en 2013

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

artículo científico publicado en 2014

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

artículo científico publicado en 2018

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2013

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

artículo científico publicado en 2016

Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2016

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

artículo científico publicado en 2018

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

artículo científico publicado en 2017

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia

artículo científico publicado en 2014

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

artículo científico publicado en 2015

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

artículo científico publicado en 2017

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

scientific article published on 09 February 2011

Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure

artículo científico publicado en 2009

Selecting the best frontline treatment in chronic myeloid leukemia

artículo científico publicado en 2015

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients

artículo científico publicado en 2016

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

artículo científico publicado en 2009

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

artículo científico publicado en 2017

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

artículo científico publicado en 2011

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

Standard management of patients with chronic myeloid leukemia

artículo científico publicado en 2009

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

scientific article published on February 2009

Suboptimal responses in chronic myeloid leukemia: implications and management strategies

artículo científico publicado en 2011

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

artículo científico publicado en 2005

Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor

artículo científico publicado en 2014

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

artículo científico publicado en 2017

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

artículo científico publicado en 2016

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia

artículo científico publicado en 2013

Targeted therapy in chronic myeloid leukemia

artículo científico publicado en 2008

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

artículo científico publicado en 2014

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

artículo científico publicado en 2013

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

artículo científico publicado en 2015

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

artículo científico publicado en 2011

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

artículo científico publicado en 2014

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

artículo científico publicado en 2016

The role of clofarabine in acute myeloid leukemia

artículo científico publicado en 2012

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

artículo científico publicado en 2015

Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes

artículo científico publicado en 2017

Thrombocytopenia in patients with myelodysplastic syndromes

artículo científico publicado en 2010

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

artículo científico publicado en 2017

Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?

artículo científico publicado en 2010

Treatment of acute lymphoblastic leukemia in older adults: now and the future

artículo científico

Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies

artículo científico publicado en 2012

Treatment of myelofibrosis in younger patients: to transplant or not?

artículo científico publicado en 2009

Treatment options for chronic myeloid leukemia

artículo científico

Treatment selection after imatinib resistance in chronic myeloid leukemia

artículo científico publicado en 2009

Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia

artículo científico publicado en 2016

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia

artículo científico publicado en 2015

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Tyrosine kinase inhibitors in acute and chronic leukemias

artículo científico

Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.

artículo científico publicado en 2009

Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions

artículo científico

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

artículo científico publicado en 2007

Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines

artículo científico publicado en 2015

Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm

artículo científico

Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia

artículo científico publicado en 2014

Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

artículo científico publicado en 2012

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2017

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

artículo científico publicado en 2015

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report

artículo científico publicado en 2016

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

artículo científico publicado en 2017

Yes, treatment for CML should continue indefinitely.

artículo científico publicado en 2017

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda